Cancer Research Meeting Calendar  Frontiers in Basic Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 792, January 15, 2007. doi: 10.1158/0008-5472.CAN-06-2925
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hou, D.-Y.
Right arrow Articles by Munn, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hou, D.-Y.
Right arrow Articles by Munn, D. H.

Immunology

Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses

De-Yan Hou1,2, Alexander J. Muller5, Madhav D. Sharma1,2, James DuHadaway5, Tinku Banerjee6, Maribeth Johnson4, Andrew L. Mellor1,3, George C. Prendergast5,7 and David H. Munn1,2

1 Immunotherapy Center and Departments of 2 Pediatrics, 3 Medicine, and 4 Biostatistics, Medical College of Georgia, Augusta, Georgia; 5 Lankenau Institute for Medical Research, Wynnewood, Pennsylvania; 6 NewLink Genetics Corporation, Ames, Iowa; and 7 Department of Pathology, Anatomy, and Cell Biology, Jefferson Medical College, Philadelphia, Pennsylvania

Requests for reprints: David H. Munn, Immunotherapy Center, Medical College of Georgia, CN-4141, Augusta, GA 30912. Phone: 706-721-7141; Fax: 706-721-8732; E-mail: dmunn{at}mcg.edu or George C. Prendergast, Lankenau Institute for Medical Research, Wynnewood, PA 19096. E-mail: prendergastgt{at}limr.org.

Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a number of biological settings. In cancer, IDO activity may help promote acquired tolerance to tumor antigens. The IDO inhibitor 1-methyl-tryptophan is being developed for clinical trials. However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biological properties, and it has been unclear which isomer might be preferable for initial development. In this study, we provide evidence that the D and L stereoisomers exhibit important cell type–specific variations in activity. The L isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell–based assays. However, the D isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte–derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. In vivo, the D isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer. The D isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of D-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice). Taken together, our findings support the suitability of D-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens. [Cancer Res 2007;67(2):792–801]




This article has been cited by other articles:


Home page
Cancer Res.Home page
F. Qian, J. Villella, P. K. Wallace, P. Mhawech-Fauceglia, J. D. Tario Jr., C. Andrews, J. Matsuzaki, D. Valmori, M. Ayyoub, P. J. Frederick, et al.
Efficacy of Levo-1-Methyl Tryptophan and Dextro-1-Methyl Tryptophan in Reversing Indoleamine-2,3-Dioxygenase-Mediated Arrest of T-Cell Proliferation in Human Epithelial Ovarian Cancer
Cancer Res., July 1, 2009; 69(13): 5498 - 5504.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Liu, Y. Peng, M. Mi, J. Guevara-Patino, D. H. Munn, N. Fu, and Y. He
Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice
J. Immunol., May 15, 2009; 182(10): 5960 - 5969.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Zeng, S. Cai, Y. Yi, Y. He, Z. Wang, G. Jiang, X. Li, and J. Du
Prevention of Spontaneous Tumor Development in a ret Transgenic Mouse Model by Ret Peptide Vaccination with Indoleamine 2,3-Dioxygenase Inhibitor 1-Methyl Tryptophan
Cancer Res., May 1, 2009; 69(9): 3963 - 3970.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood, March 12, 2009; 113(11): 2394 - 2401.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. C. O'Connor, M. A. Lawson, C. Andre, E. M. Briley, S. S. Szegedi, J. Lestage, N. Castanon, M. Herkenham, R. Dantzer, and K. W. Kelley
Induction of IDO by Bacille Calmette-Guerin Is Responsible for Development of Murine Depressive-Like Behavior
J. Immunol., March 1, 2009; 182(5): 3202 - 3212.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-I. Jeong, S. W. Kim, I. D. Jung, J. S. Lee, J. H. Chang, C.-M. Lee, S. H. Chun, M.-S. Yoon, G. T. Kim, S. W. Ryu, et al.
Curcumin Suppresses the Induction of Indoleamine 2,3-Dioxygenase by Blocking the Janus-activated Kinase-Protein Kinase C{delta}-STAT1 Signaling Pathway in Interferon-{gamma}-stimulated Murine Dendritic Cells
J. Biol. Chem., February 6, 2009; 284(6): 3700 - 3708.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M.-C. Yen, C.-C. Lin, Y.-L. Chen, S.-S. Huang, H.-J. Yang, C.-P. Chang, H.-Y. Lei, and M.-D. Lai
A Novel Cancer Therapy by Skin Delivery of Indoleamine 2,3-Dioxygenase siRNA
Clin. Cancer Res., January 15, 2009; 15(2): 641 - 649.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. E.D. Chamuleau, A. A. van de Loosdrecht, C. J. Hess, J. J.W.M. Janssen, A. Zevenbergen, R. Delwel, P. J.M. Valk, B. Lowenberg, and G. J. Ossenkoppele
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
Haematologica, December 1, 2008; 93(12): 1894 - 1898.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Yoshida, K. Ino, Y. Ishida, H. Kajiyama, E. Yamamoto, K. Shibata, M. Terauchi, A. Nawa, H. Akimoto, O. Takikawa, et al.
Overexpression of Indoleamine 2,3-Dioxygenase in Human Endometrial Carcinoma Cells Induces Rapid Tumor Growth in a Mouse Xenograft Model
Clin. Cancer Res., November 15, 2008; 14(22): 7251 - 7259.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. J. Muller, M. D. Sharma, P. R. Chandler, J. B. DuHadaway, M. E. Everhart, B. A. Johnson III, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, et al.
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
PNAS, November 4, 2008; 105(44): 17073 - 17078.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
O. J. Finn
Cancer Immunology
N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Ino, E. Yamamoto, K. Shibata, H. Kajiyama, N. Yoshida, M. Terauchi, A. Nawa, T. Nagasaka, O. Takikawa, and F. Kikkawa
Inverse Correlation between Tumoral Indoleamine 2,3-Dioxygenase Expression and Tumor-Infiltrating Lymphocytes in Endometrial Cancer: Its Association with Disease Progression and Survival
Clin. Cancer Res., April 15, 2008; 14(8): 2310 - 2317.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Lob, A. Konigsrainer, R. Schafer, H.-G. Rammensee, G. Opelz, and P. Terness
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells
Blood, February 15, 2008; 111(4): 2152 - 2154.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
T. F. Gajewski, E. A. Grimm, B. J. Nickoloff, and A. T. Weeraratna
New Potential Therapeutic Targets in Melanoma
ASCO Educational Book, January 1, 2008; 2008(1): 404 - 407.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Riesenberg, C. Weiler, O. Spring, M. Eder, A. Buchner, T. Popp, M. Castro, R. Kammerer, O. Takikawa, R. A. Hatz, et al.
Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma
Clin. Cancer Res., December 1, 2007; 13(23): 6993 - 7002.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
T. F. Gajewski
Failure at the Effector Phase: Immune Barriers at the Level of the Melanoma Tumor Microenvironment
Clin. Cancer Res., September 15, 2007; 13(18): 5256 - 5261.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Metz, J. B. DuHadaway, U. Kamasani, L. Laury-Kleintop, A. J. Muller, and G. C. Prendergast
Novel Tryptophan Catabolic Enzyme IDO2 Is the Preferred Biochemical Target of the Antitumor Indoleamine 2,3-Dioxygenase Inhibitory Compound D-1-Methyl-Tryptophan
Cancer Res., August 1, 2007; 67(15): 7082 - 7087.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.